肠易激综合征

Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91.

• 全文
• 摘要

Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016 May;150(6):1393-407.

• 摘要

Weinberg DS, Smalley W, Heidelbaugh JJ, et al; American Gastroenterological Association. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014 Nov;147(5):1146-8.

• 全文
• 摘要

Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43.

• 摘要

1.  Drossman DA, Camilleri M, Mayes FA. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):2108-31.

• 摘要

2.  Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91.

• 全文
• 摘要

3.  Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016 May;150(6):1393-407.

• 摘要

4.  Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012 Aug 8;143(5):1179-87.e3.

• 全文
• 摘要

5.  Longstreth GF, Wolde-Tsadik G. Irritable bowel syndrome type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates. Dig Dis Sci. 1993 Sep;38(9):1581-9.

• 摘要

6.  World Gastroenterology Organisation. Irritable bowel syndrome: a global perspective. 2015 [internet publication].

• 全文

7.  Ford AC, Talley NJ. Irritable bowel syndrome. BMJ. 2012 Sep 4;345:e5836.

• 摘要

8.  Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver. 2011 Sep;5(3):253-66.

• 全文
• 摘要

9.  Boyce PM, Koloski NA, Taley NJ. Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol. 2000 Nov;95(11):3176-83. Erratum in Am J Gastroenterol. 2001 Apr;96(4):1319.

10.  Gwee KA, Wee S, Wong ML, et al. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. Am J Gastroenterol. 2004 May;99(5):924-31.

11.  Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002 Aug;97(8):1910-5.

• 摘要

12.  Walker EA, Katon WJ, Roy-Byrne PP, et al. Histories of sexual victimization in patients with irritable bowel syndrome or inflammatory bowel disease. Am J Psychiatry. 1993 Oct;150(10):1502-6.

• 摘要

13.  Devanarayana NM, Rajindrajith S, Pathmeswaran A, et al. Epidemiology of irritable bowel syndrome in children and adolescents in Asia. J Pediatr Gastroenterol Nutr. 2015 Jun;60(6):792-8.

• 摘要

14.  Ahmad OF, Akbar A. Microbiome, antibiotics and irritable bowel syndrome. Br Med Bull. 2016 Dec;120(1):91-9.

• 全文
• 摘要

15.  Liu HN, Wu H, Chen YZ, et al. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis. Dig Liver Dis. 2017 Apr;49(4):331-7.

• 摘要

16.  Kellow JE, Azpiroz F, Delvaux M, et al. Applied principles of neurogastroenterology: physiology/motility sensation. Gastroenterology. 2006 Apr;130(5):1412-20.

• 摘要

17.  Drossman DA, Talley NJ, Leserman J, et al. Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med. 1995 Nov 15;123(10):782-94.

• 摘要

18.  Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology. 2017 Apr;152(5):1042-54.

• 摘要

19.  National Institute for Health and Care Excellence. Irritable bowel syndrome in adults: diagnosis and management. April 2017. http://www.nice.org.uk/ (Internet publication).

• 全文

20.  Lewis NR, Scott BB. Systematic review: the use of serology to exclude or diagnose coeliac disease (a comparison of the endomysial and tissue transglutaminase antibody tests). Aliment Pharmacol Ther. 2006 Jul 1;24(1):47-54.

• 全文
• 摘要

21.  Irvine AJ, Chey WD, Ford AC. Screening for celiac disease in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2017 Jan;112(1):65-76.

• 全文
• 摘要

22.  Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013 Nov;17(55):1-211.

• 摘要

23.  Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015 Mar;110(3):444-54.

• 摘要

24.  Kamp EJ, Kane JS, Ford AC. Irritable bowel syndrome and microscopic colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016 May;14(5):659-68.

• 摘要

25.  Manning AP, Thompson WG, Heaton KW, et al. Towards a positive diagnosis of irritable bowel. BMJ. 1978 Sep 2;2(6138):653-4.

26.  Weinberg DS, Smalley W, Heidelbaugh JJ, et al; American Gastroenterological Association. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014 Nov;147(5):1146-8.

• 全文
• 摘要

27.  Zhang Y, Li L, Guo C, et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016 Jun 13;16(1):62.

• 全文
• 摘要

28.  Brenner DM, Moeller MJ, Chey WD, et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009 Apr;104(4):1033-49.

• 摘要

29.  O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005 Mar;128(3):541-51.

• 摘要

30.  Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014 Jan;146(1):67-75.

• 全文
• 摘要

31.  Ahmad OF, Akbar A. Dietary treatment of irritable bowel syndrome. Br Med Bull. 2015 Mar;113(1):83-90.

• 摘要

32.  Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr. 2016 Apr;55(3):897-906.

• 全文
• 摘要

33.  Mansueto P, Seidita A, D'Alcamo A, et al. Role of FODMAPs in patients with irritable bowel syndrome. Nutr Clin Pract. 2015 Oct;30(5):665-82.

• 全文
• 摘要

34.  Varjú P, Farkas N, Hegyi P I et al. Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: a meta-analysis of clinical studies. PLoS One. 2017 Aug 14;12(8):e0182942.

• 全文
• 摘要

35.  Altobelli E, Del Negro V, Angeletti PM, et al. Low-FODMAP diet improves irritable bowel syndrome symptoms: a meta-analysis. Nutrients. 2017 Aug 26;9(9):E940.

• 全文
• 摘要

36.  McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017 Jul;66(7):1241-51.

• 摘要

37.  Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015 Nov;149(6):1399-407.

• 全文
• 摘要

38.  Nagarajan N, Morden A, Bischof D, et al. The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2015 Sep;27(9):1002-10.

• 摘要

39.  Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009 Feb 1;29(3):329-41

• 摘要

40.  Li F, Fu T, Tong WD, et al. Lubiprostone is effective in the treatment of chronic idiopathic constipation and irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2016 Apr;91(4):456-68.

• 摘要

41.  Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010 Dec;139(6):1877-86.

• 摘要

42.  Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012 Nov;107(11):1702-12.

• 全文
• 摘要

43.  Shah ED, Kim HM, Schoenfeld P. Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis. Am J Gastroenterol. 2018 Mar;113(3):329-38.

• 摘要

44.  Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43.

• 摘要

45.  Andresen V, Montori VM, Keller J, et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2008 May;6(5):545-55.

• 摘要

46.  Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013 Aug;145(2):329-38.

• 全文
• 摘要

47.  US Food and Drug Administration. FDA drug safety communication: FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder. March 2017 [internet publication].

• 全文

48.  National Institute for Health and Care Excellence. Eluxadoline for treating irritable bowel syndrome with diarrhoea. August 2017 [internet publication].

• 全文

49.  Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017 May;66(5):966-74.

• 摘要

50.  Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and meta analysis. Am J Gastroenterol. 1998 Jul;93(7):1131-5.

• 摘要

51.  Ford AC,Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008 Nov 13;337:a2313.

• 全文
• 摘要

52.  Rahimi R, Nikfar S, Rezaie A, et al. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2009 Apr 7;15(13):1548-53.

• 全文
• 摘要

53.  Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006 Aug;55(8):1095-103.

• 摘要

54.  Xie C, Tang Y, Wang Y, et al. Efficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysis. PLoS One. 2015 Aug 7;10(8):e0127815.

• 全文
• 摘要

55.  Häuser W, Hagl M, Schmierer A, et al. The efficacy, safety and applications of medical hypnosis. Dtsch Arztebl Int. 2016 Apr 29;113(17):289-96.

• 全文
• 摘要

56.  Laird KT, Tanner-Smith EE, Russell AC, et al. Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: a systematic review and meta-analysis. Clin Psychol Rev. 2017 Feb;51:142-52.

• 全文
• 摘要

57.  Radziwon CD, Lackner JM. Cognitive behavioral therapy for IBS: how useful, how often, and how does it work? Curr Gastroenterol Rep. 2017 Aug 17;19(10):49.

• 摘要

58.  Windgassen S, Moss-Morris R, Chilcot J, et al. The journey between brain and gut: a systematic review of psychological mechanisms of treatment effect in irritable bowel syndrome. Br J Health Psychol. 2017 Nov;22(4):701-36.

• 摘要

59.  Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22-32.

• 全文
• 摘要

60.  Tack J. Antibiotic therapy for the irritable bowel syndrome. N Engl J Med. 2011 Jan 6;364(1):81-2.

• 全文
• 摘要

61.  Li J, Zhu W, Liu W, et al. Rifaximin for irritable bowel syndrome: a meta-analysis of randomized placebo-controlled trials. Medicine (Baltimore). 2016 Jan;95(4):e2534.

• 全文
• 摘要

62.  Tseng PT, Zeng BS, Chen YW, et al. A meta-analysis and systematic review of the comorbidity between irritable bowel syndrome and bipolar disorder. Medicine (Baltimore). 2016 Aug;95(33):e4617.

• 全文
• 摘要

63.  Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2017 Oct 31. pii: S2468-1253(17)30338-2.

• 摘要

64.  Simrén M, Barbara G, Flint HJ, et al; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan;62(1):159-76.

• 全文
• 摘要

65.  Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016 Feb;150(2):358-66.

• 全文
• 摘要

66.  Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014 Oct;63(10):1617-25.

• 全文
• 摘要

67.  Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial. Am J Gastroenterol. 2017 May;112(5):763-74.

• 全文
• 摘要

68.  Jung HK, Choung R, Locke G. Diarrhea predominant irritable bowel syndrome is associated with diverticulosis: a population based study. Am J Gastroenterol. 2010 Mar;105(3):652-61.

• 全文
• 摘要